Engaging the lysosomal compartment to combat B cell malignancies

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Engaging the lysosomal compartment to combat B cell malignancies. / Gronbaek, K.; Jaattela, M.

I: Journal of Clinical Investigation, Bind 119, Nr. 8, 2009, s. 2133-2136.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Gronbaek, K & Jaattela, M 2009, 'Engaging the lysosomal compartment to combat B cell malignancies', Journal of Clinical Investigation, bind 119, nr. 8, s. 2133-2136.

APA

Gronbaek, K., & Jaattela, M. (2009). Engaging the lysosomal compartment to combat B cell malignancies. Journal of Clinical Investigation, 119(8), 2133-2136.

Vancouver

Gronbaek K, Jaattela M. Engaging the lysosomal compartment to combat B cell malignancies. Journal of Clinical Investigation. 2009;119(8):2133-2136.

Author

Gronbaek, K. ; Jaattela, M. / Engaging the lysosomal compartment to combat B cell malignancies. I: Journal of Clinical Investigation. 2009 ; Bind 119, Nr. 8. s. 2133-2136.

Bibtex

@article{3bfa18d059ab11df928f000ea68e967b,
title = "Engaging the lysosomal compartment to combat B cell malignancies",
abstract = "The combination of rituximab, a type I anti-CD20 mAb, with conventional chemotherapy has significantly improved the outcome of patients with B cell malignancies. Regardless of this success, many patients still relapse with therapy-resistant disease, highlighting the need for the development of mAbs with higher capacity to induce programmed cell death. The so-called type II anti-CD20 mAbs (e.g., tositumomab) that trigger caspase-independent B cell lymphoma cell death in vitro and show superior efficacy as compared with rituximab in eradicating target cells in mouse models are emerging as the next generation of therapeutic anti-CD20 mAbs. In this issue of the JCI, Ivanov and colleagues identify the lysosomal compartment as a target for type II mAbs (see the related article beginning on page 2143). These data encourage the further clinical development of type II mAbs as well as other lysosome-targeting drugs in the treatment of B cell malignancies Udgivelsesdato: 2009/8",
author = "K. Gronbaek and M. Jaattela",
year = "2009",
language = "English",
volume = "119",
pages = "2133--2136",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "American Society for Clinical Investigation",
number = "8",

}

RIS

TY - JOUR

T1 - Engaging the lysosomal compartment to combat B cell malignancies

AU - Gronbaek, K.

AU - Jaattela, M.

PY - 2009

Y1 - 2009

N2 - The combination of rituximab, a type I anti-CD20 mAb, with conventional chemotherapy has significantly improved the outcome of patients with B cell malignancies. Regardless of this success, many patients still relapse with therapy-resistant disease, highlighting the need for the development of mAbs with higher capacity to induce programmed cell death. The so-called type II anti-CD20 mAbs (e.g., tositumomab) that trigger caspase-independent B cell lymphoma cell death in vitro and show superior efficacy as compared with rituximab in eradicating target cells in mouse models are emerging as the next generation of therapeutic anti-CD20 mAbs. In this issue of the JCI, Ivanov and colleagues identify the lysosomal compartment as a target for type II mAbs (see the related article beginning on page 2143). These data encourage the further clinical development of type II mAbs as well as other lysosome-targeting drugs in the treatment of B cell malignancies Udgivelsesdato: 2009/8

AB - The combination of rituximab, a type I anti-CD20 mAb, with conventional chemotherapy has significantly improved the outcome of patients with B cell malignancies. Regardless of this success, many patients still relapse with therapy-resistant disease, highlighting the need for the development of mAbs with higher capacity to induce programmed cell death. The so-called type II anti-CD20 mAbs (e.g., tositumomab) that trigger caspase-independent B cell lymphoma cell death in vitro and show superior efficacy as compared with rituximab in eradicating target cells in mouse models are emerging as the next generation of therapeutic anti-CD20 mAbs. In this issue of the JCI, Ivanov and colleagues identify the lysosomal compartment as a target for type II mAbs (see the related article beginning on page 2143). These data encourage the further clinical development of type II mAbs as well as other lysosome-targeting drugs in the treatment of B cell malignancies Udgivelsesdato: 2009/8

M3 - Journal article

VL - 119

SP - 2133

EP - 2136

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 8

ER -

ID: 19600237